\u30b0\u30ed\u30fc\u30d0\u30eb\u306b\u4e8b\u696d\u5c55\u958b\u3059\u308b\u5927\u624b\u88fd\u85ac\u30e1\u30fc\u30ab\u30fc\u304c\u3001\u65e5\u672c\u3092\u542b\u3080\u30a2\u30b8\u30a2\u30fb\u30aa\u30bb\u30a2\u30cb\u30a2\u5730\u57df\u306b\u304a\u3044 \u3066\u300c\u304c\u3093\u514d\u75ab\u300d\u9818\u57df\u306e\u521d\u671f\u6bb5\u968e\u306b\u3042\u308b\u7814\u7a76\u3092\u63a2\u3057\u3066\u3044\u307e\u3059\u3002\u5354\u696d\u306e\u53ef\u80fd\u6027\u3068\u3057\u3066\u3001\u7814\u7a76\u6bb5\u968e \u306b\u5fdc\u3058\u3066\u5171\u540c\u7814\u7a76\/\u958b\u767a\u3001\u77e5\u8ca1\u306a\u3069\u306e\u30a2\u30bb\u30c3\u30c8\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u304c\u8003\u3048\u3089\u308c\u307e\u3059\u3002<\/p>\n
\u6c42\u3081\u3066\u3044\u308b\u7814\u7a76\u5206\u91ce\u306e\u4f8b\uff08\u5fc5\u305a\u3057\u3082\u3053\u306e\u4f8b\u306b\u5408\u81f4\u3057\u306a\u304f\u3066\u3082\u69cb\u3044\u307e\u305b\u3093\uff09:<\/p>\n
\u56fa\u5f62\u304c\u3093\u3068\u8840\u6db2\u304c\u3093\u6cbb\u7642\u306b\u304a\u3044\u3066\u3001\u65e2\u5b58\u306e\u6cbb\u7642\u6cd5\u3092\u51cc\u3050\u9ad8\u5ea6\u306b\u30a4\u30ce\u30d9\u30fc\u30c6\u30a3\u30d6\u306a\u30a2\u30d7\u30ed\u30fc \u30c1\u3092\u6c42\u3081\u3066\u3044\u307e\u3059\u3002\u30a2\u30d7\u30ed\u30fc\u30c1\u306b\u306f\u3001\u65b0\u898f\u306e\u4f4e\u5206\u5b50\u85ac\u5264(\u30da\u30a4\u30ed\u30fc\u30c9)\u3084\u6b21\u4e16\u4ee3\u306eT\u7d30\u80de \u30a8\u30f3\u30b2\u30fc\u30b8\u3001CARTs(CAR-modified T cells)\u304c\u542b\u307e\u308c\u307e\u3059\u3002\u4f9d\u983c\u5143\u4f01\u696d\u304c\u81ea\u793e\u3067\u81e8\u5e8a\u7684 \u306b\u5148\u4f8b\u306e\u3042\u308b\u30bf\u30fc\u30b2\u30c3\u30c8\u3092\u6d3b\u7528\u3059\u308b\u3053\u3068\u3067\u3001\u3053\u308c\u3089\u306e\u65b0\u898f\u30d7\u30e9\u30c3\u30c8\u30d5\u30a9\u30fc\u30e0\u306e\u53d6\u6271\u3084\u3059\u3055\u3084\u5206\u5316\u80fd\u3001\u3055\u3089\u306b\u8ffd\u52a0\u306e\u304c\u3093\u306e\u5146\u5019\u3078\u306e\u62e1\u5f35\u306e\u9069\u6b63\u3092\u8a55\u4fa1\u3057\u305f\u3044\u3068\u8003\u3048\u3066\u3044\u307e\u3059\u3002<\/p>\n
\u7b2c\u4e00\u4e16\u4ee3\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u963b\u5bb3\u5264\u306f\u3001\u9ed2\u8272\u816b(melanoma)\u3084\u975e\u5c0f\u7d30\u80de\u80ba\u304c\u3093 (NSCLC)\u3092\u542b\u3080\u9ad8\u5909\u7570\u6027\u4f53\u3092\u30b5\u30d6\u30bf\u30a4\u30d7\u3068\u3059\u308b\u514d\u75ab\u539f\u751f\u816b\u760d\u306b\u5bfe\u3059\u308b\u9855\u8457\u306a\u6709\u52b9\u6027\u3068\u3001\u816b\u760d\u6d78\u6f64\u6027\u30ea\u30f3\u30d1\u7403(TILs)\u306e\u5b58\u5728\u3092\u5b9f\u8a3c\u3057\u307e\u3057\u305f\u3002PD-1(Programmed Death-1) \u306b\u5bfe\u3059\u308b\u8457\u3057\u3044\u975e\u53cd\u5fdc\u6027\u304c\u3042\u308b\u7269\u8cea\u304c\u5b58\u5728\u3057\u3001\u4e14\u3064\u305d\u306e\u7269\u8cea\u306f\u4f4e\u514d\u75ab\u539f\u751f\u816b\u760d(cold tumor)\u3068\u547c\u3070\u308c\u3066\u3044\u308bTILs\u306e\u767a\u73fe\u306e\u4f4e\u6e1b\u3068\u76f8\u95a2\u95a2\u4fc2\u3092\u6301\u3064\u3053\u3068\u304b\u3089\u3001\u3053\u306e\u4f01\u696d\u306f\u3001A)\u4f4e\u514d\u75ab\u539f\u6027\u816b\u760d\u304b\u3089\u9ad8\u514d\u75ab\u539f\u751f\u816b\u760d\u306b\u5909\u7570\u3055\u305b\u308b\u53ef\u80fd\u6027\u306e\u3042\u308b\u5148\u5929\u6027\u514d\u75ab\u7d30\u80de\u3078\u306e\u30a2\u30d7\u30ed\u30fc\u30c1\u3001B)\u65e2\u5b58\u306eIgG\u30d9\u30fc\u30b9\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u6cbb\u7642\u6cd5\u3068\u5dee\u5225\u5316\u3067\u304d\u308b\u53ef\u80fd\u6027\u304c\u3042\u308b\u6b21\u4e16 \u4ee3\u306e\u514d\u75ab\u30c1\u30a7\u30c3\u30af\u30dd\u30a4\u30f3\u30c8\u30e2\u30b8\u30e5\u30ec\u30fc\u30bf\u30fc\u306b\u95a2\u308f\u308b\u7814\u7a76\u306b\u8208\u5473\u3092\u6301\u3063\u3066\u3044\u307e\u3059\u3002<\/p>\n
\u5bfe\u8c61\u3068\u306a\u308b\u7814\u7a76\u6bb5\u968e:<\/p>\n
——————————————————–<\/p>\n
keywords1: cancer immuno-therapy,anticancer immunity,immune checkpoint,metabolic immuno- oncology,cancer vaccination,adoptive cell therapy,immuno-oncology
\nkeywords2: \u5171\u540c\u7814\u7a76,\u30e9\u30a4\u30bb\u30f3\u30b9
\nlanguage : -JP\/EN
\ninfocode : m02y12cB30r01
\nN-number : 12_I25<\/p>\n","protected":false},"author":1,"featured_media":1534,"template":"","meta":{"_company_name":"Japan Technology Group","_job_location":"","_application":"raoki.keisen@gmail.com","_company_tagline":"\u5927\u624b\u88fd\u85ac\u30e1\u30fc\u30ab\u30fc\u304c\u3001\u65e5\u672c\u3092\u542b\u3080\u30a2\u30b8\u30a2\u30fb\u30aa\u30bb\u30a2\u30cb\u30a2\u5730\u57df\u306b\u304a\u3044 \u3066\u300c\u304c\u3093\u514d\u75ab\u300d\u9818\u57df\u306e\u521d\u671f\u6bb5\u968e\u306b\u3042\u308b\u7814\u7a76\u3092\u63a2\u3057\u3066\u3044\u307e\u3059\u3002","_company_video":"","_company_website":"https:\/\/japantechnologygroup.jp\/index.html","_company_twitter":"","_filled":0,"_featured":0,"_remote_position":0,"_job_salary":"","_job_salary_currency":"","_job_salary_unit":""},"job_listing_region":[106],"job-categories":[68,69,70],"job-types":[52],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-listings\/974"}],"collection":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-listings"}],"about":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/types\/job_listing"}],"author":[{"embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/users\/1"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/media\/1534"}],"wp:attachment":[{"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/media?parent=974"}],"wp:term":[{"taxonomy":"job_listing_region","embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job_listing_region?post=974"},{"taxonomy":"job_listing_category","embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-categories?post=974"},{"taxonomy":"job_listing_type","embeddable":true,"href":"https:\/\/www.nikola.jp\/needs\/wp-json\/wp\/v2\/job-types?post=974"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}